1. Psoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort study.
- Author
-
Sanz Segura, Patricia, Gomollón, Fernando, Casas, Diego, Iborra, Marisa, Vela, Milagros, Fernández-Clotet, Agnès, Muñoz, Roser, García de la Filia, Irene, García Prada, María, Ferrer Rosique, Juan Ángel, García, María José, de Francisco, Ruth, Arias, Lara, Barrio, Jesús, Guerra, Iván, Ponferrada, Ángel, Gisbert, Javier P., Carrillo-Palau, Marta, Calvet, Xavier, and Márquez-Mosquera, Lucía
- Abstract
some patients with inflammatory bowel disease (IBD) treated with antiTNF develop drug-induced psoriasis (antiTNF-IP). Several therapeutic strategies are possible. to assess the management of antiTNF-IP in IBD, and its impact in both diseases. patients with antiTNF-IP from ENEIDA registry were included. Therapeutic strategy was classified as continuing the same antiTNF, stopping antiTNF, switch to another antiTNF or swap to a non-antiTNF biologic. IP severity and IBD activity were assessed at baseline and 16, 32 and 54 weeks. 234 patients were included. At baseline, antiTNF-IP was moderate-severe in 60 % of them, and IBD was in remission in 80 %. Therapeutic strategy was associated to antiTNF-IP severity (p < 0.001). AntiTNF-IP improved at week 54 with all strategies, but continuing with the same antiTNF showed the worst results (p = 0.042). Among patients with IBD in remission, relapse was higher in those who stopped antiTNF (p = 0.025). In multivariate analysis, stopping antiTNF, trunk and palms and soles location were associated with antiTNF-IP remission; female sex and previous surgery in Crohn´s disease with IBD relapse. skin lesions severity and IBD activity seem to determine antiTNF-IP management. Continuing antiTNF in mild antiTNF-IP, and swap to ustekinumab or switch to another antiTNF in moderate-severe cases, are suitable strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF